Karoline Leuzinger1,2, Rainer Gosert1, Kirstine K Søgaard3,4, Klaudia Naegele1, Julia Bielicki5, Tim Roloff3,4, Roland Bingisser6, Christian H Nickel6, Nina Khanna7, Sarah Tschudin Sutter7, Andreas F Widmer7, Katharina Rentsch8, Hans Pargger9, Martin Siegemund9, Daiana Stolz10, Michael Tamm10, Stefano Bassetti11, Michael Osthoff11, Manuel Battegay7, Adrian Egli3,4, Hans H Hirsch1,2,7. 1. Clinical Virology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland. 2. Transplantation & Clinical Virology, Department Biomedicine, University of Basel, Basel, Switzerland. 3. Applied Microbiology Research, Laboratory Medicine, Department Biomedicine, University of Basel, Basel, Switzerland. 4. Clinical Bacteriology and Mycology, Laboratory Medicine, University Hospital Basel, Basel, Switzerland. 5. Pediatric Infectious Diseases & Hospital Epidemiology, University Children Hospital Basel, Basel, Switzerland. 6. Emergency Medicine, University Hospital Basel, Basel, Switzerland. 7. Infectious Diseases & Hospital Epidemiology, Basel, Switzerland. 8. Clinical Chemistry, Laboratory Medicine, University Hospital Basel, Basel, Switzerland. 9. Intensive Care Unit, University Hospital Basel, Basel, Switzerland. 10. Clinic of Pneumology and Pulmonary Cell Research, University Hospital Basel, Basel, Switzerland. 11. Internal Medicine, University Hospital Basel, Basel, Switzerland.
Abstract
OBJECTIVES: Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is key to the clinical and epidemiological assessment of CoVID-19. We cross-validated manual and automated high-throughput testing for SARS-CoV-2-RNA, evaluated SARS-CoV-2 loads in nasopharyngeal-oropharyngeal swabs (NOPS), lower respiratory fluids, and plasma, and analyzed detection rates after lockdown and relaxation measures. METHODS: Basel-S-gene, Roche-E-gene, and Roche-cobas®6800-Target1 and Target2 were prospectively validated in 1344 NOPS submitted during the first pandemic peak (Week 13). Follow-up cohort (FUP) 1, 2, and 3 comprised 10,999, 10,147, and 19,389 NOPS submitted during a 10-week period until Weeks 23, 33, and 43, respectively. RESULTS: Concordant results were obtained in 1308 cases (97%), including 97 (9%) SARS-CoV-2-positives showing high quantitative correlations (Spearman's r > .95; p < .001) for all assays and high precision by Bland-Altman analysis. Discordant samples (N = 36, 3%) had significantly lower SARS-CoV-2 loads (p < .001). Following lockdown, detection rates declined to <1% in FUP-1, reducing single-test positive predictive values from 99.3% to 85.1%. Following relaxation, rates flared up to 4% and 12% in FUP-2 and -3, but infected patients were younger than during lockdown (34 vs. 52 years, p < .001). In 261 patients providing 936 NOPS, SARS-CoV-2 loads declined by three orders of magnitude within 10 days postdiagnosis (p < .001). SARS-CoV-2 loads in NOPS correlated with those in time-matched lower respiratory fluids or in plasma but remained detectable in some cases with negative follow-up NOPS, respectively. CONCLUSION: Manual and automated assays significantly correlated qualitatively and quantitatively. Following a successful lockdown, declining positive predictive values require independent dual-target confirmation for reliable assessment. Confirmatory and quantitative follow-up testing should be obtained within <5 days and consider lower respiratory fluids in symptomatic patients with SARS-CoV-2-negative NOPS.
OBJECTIVES: Detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is key to the clinical and epidemiological assessment of CoVID-19. We cross-validated manual and automated high-throughput testing for SARS-CoV-2-RNA, evaluated SARS-CoV-2 loads in nasopharyngeal-oropharyngeal swabs (NOPS), lower respiratory fluids, and plasma, and analyzed detection rates after lockdown and relaxation measures. METHODS: Basel-S-gene, Roche-E-gene, and Roche-cobas®6800-Target1 and Target2 were prospectively validated in 1344 NOPS submitted during the first pandemic peak (Week 13). Follow-up cohort (FUP) 1, 2, and 3 comprised 10,999, 10,147, and 19,389 NOPS submitted during a 10-week period until Weeks 23, 33, and 43, respectively. RESULTS: Concordant results were obtained in 1308 cases (97%), including 97 (9%) SARS-CoV-2-positives showing high quantitative correlations (Spearman's r > .95; p < .001) for all assays and high precision by Bland-Altman analysis. Discordant samples (N = 36, 3%) had significantly lower SARS-CoV-2 loads (p < .001). Following lockdown, detection rates declined to <1% in FUP-1, reducing single-test positive predictive values from 99.3% to 85.1%. Following relaxation, rates flared up to 4% and 12% in FUP-2 and -3, but infectedpatients were younger than during lockdown (34 vs. 52 years, p < .001). In 261 patients providing 936 NOPS, SARS-CoV-2 loads declined by three orders of magnitude within 10 days postdiagnosis (p < .001). SARS-CoV-2 loads in NOPS correlated with those in time-matched lower respiratory fluids or in plasma but remained detectable in some cases with negative follow-up NOPS, respectively. CONCLUSION: Manual and automated assays significantly correlated qualitatively and quantitatively. Following a successful lockdown, declining positive predictive values require independent dual-target confirmation for reliable assessment. Confirmatory and quantitative follow-up testing should be obtained within <5 days and consider lower respiratory fluids in symptomatic patients with SARS-CoV-2-negative NOPS.
Authors: Gert Zimmer; Tobias Derfuss; Nicholas S R Sanderson; Ilaria Callegari; Mika Schneider; Giuliano Berloffa; Tobias Mühlethaler; Sebastian Holdermann; Edoardo Galli; Tim Roloff; Renate Boss; Laura Infanti; Nina Khanna; Adrian Egli; Andreas Buser Journal: EMBO Rep Date: 2022-05-12 Impact factor: 9.071
Authors: Fanny Wegner; Tim Roloff; Gilbert Greub; Adrian Egli; Michael Huber; Samuel Cordey; Alban Ramette; Yannick Gerth; Claire Bertelli; Madlen Stange; Helena M B Seth-Smith; Alfredo Mari; Karoline Leuzinger; Lorenzo Cerutti; Keith Harshman; Ioannis Xenarios; Philippe Le Mercier; Pascal Bittel; Stefan Neuenschwander; Onya Opota; Jonas Fuchs; Marcus Panning; Charlotte Michel; Marie Hallin; Thomas Demuyser; Ricardo De Mendonca; Paul Savelkoul; Jozef Dingemans; Brian van der Veer; Stefan A Boers; Eric C J Claas; Jordy P M Coolen; Willem J G Melchers; Marianne Gunell; Teemu Kallonen; Tytti Vuorinen; Antti J Hakanen; Eva Bernhoff; Marit Andrea Klokkhammer Hetland; Hadar Golan Berman; Sheera Adar; Jacob Moran-Gilad; Dana G Wolf; Stephen L Leib; Oliver Nolte; Laurent Kaiser; Stefan Schmutz; Verena Kufner; Maryam Zaheri; Alexandra Trkola; Hege Vangstein Aamot; Hans H Hirsch Journal: J Clin Microbiol Date: 2021-11-10 Impact factor: 5.948
Authors: Simone Cesaro; Per Ljungman; Malgorzata Mikulska; Hans H Hirsch; Marie von Lilienfeld-Toal; Catherine Cordonnier; Sylvain Meylan; Varun Mehra; Jan Styczynski; Francesco Marchesi; Caroline Besson; Fausto Baldanti; Raul Cordoba Masculano; Gernot Beutel; Herman Einsele; Elie Azoulay; Johan Maertens; Rafael de la Camara; Livio Pagano Journal: Leukemia Date: 2022-04-29 Impact factor: 12.883
Authors: Noemi R Simon; Andrea S Jauslin; Marco Rueegg; Raphael Twerenbold; Maurin Lampart; Stefan Osswald; Stefano Bassetti; Sarah Tschudin-Sutter; Martin Siegemund; Christian H Nickel; Roland Bingisser Journal: J Clin Med Date: 2021-06-02 Impact factor: 4.241
Authors: Vera Dalla Via; Matthias von Rotz; Veronika Bättig; Karoline Leuzinger; Hans H Hirsch; Jakob Passweg; Georg Stüssi; Michael Medinger Journal: SN Compr Clin Med Date: 2021-07-20